Kisho

MedPacto, Inc. — Rare Disease Pipeline | Kisho

MedPacto, Inc.

Other

Orphan Designations

0 approved, 3 designated

FDA Approvals

Active Trials

200 recruiting

Rare Diseases

across 7 areas

News (30d)

Quiet

MedPacto, Inc. is a company with 4 orphan drug designations across 5 rare diseases. Active clinical trials in 1 indication.

Competitive Landscape

Diversified Portfolio

Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.

Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA

Approved: 0

In Trials: 1

Designated Only: 4

5 total diseases

Disease	Drug(s)	Stage
gastric cancer	Vactosertib	Des.TrialAppr.
hepatocellular carcinoma	N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline	Des.TrialAppr.
malignant pancreatic neoplasm	Vactosertib	Des.TrialAppr.
osteosarcoma	vactosertib	Des.TrialAppr.
sarcoma	-	Des.TrialAppr.